Physician profile
William J Thomas
NPI 1891773024
$55,543.97
in general payments reported to CMS, 2019-2025
36 companies · $450 in 2025
The $450 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,371 · 2020: $7,071 · 2021: $17K · 2022: $12K · 2023: $15K · 2024: $1,864 · 2025: $450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $3,502 · Travel and Lodging: $766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,162.50 |
| Food and Beverage | $3,502.28 |
| Travel and Lodging | $765.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $36,945.42 | 2019-2023 | Jardiance |
| Lilly USA, LLC | $6,218.75 | 2020-2023 | Jardiance |
| Edwards Lifesciences Corporation | $4,268.24 | 2019-2025 | Sapien 3 Ultra Resilia, Pascal, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abbott Laboratories | $2,450.51 | 2019-2024 | Mitraclip, Perclose Proglide, Perclose Prostyle |
| Boston Scientific Corporation | $1,795.86 | 2019-2025 | Watchman Flx, General - Ep |
| Novartis Pharmaceuticals Corporation | $700.47 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $341.02 | 2019-2024 | Lifevest |
| Medtronic Vascular, INC. | $323.04 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $317.71 | 2019-2024 | Xarelto |
| Astellas Pharma US INC | $264.70 | 2019 | |
| Amgen INC. | $241.58 | 2020-2024 | Repatha |
| Pfizer INC. | $196.37 | 2019-2024 | |
| Cardiva Medical, INC. | $190.21 | 2022-2024 | Savvywire, Cardiva Vascade Mvp Vvcs 6-12f |
| Cardiac Dimensions, INC. | $115.00 | 2025 | |
| Sanofi-Aventis U.S. LLC | $113.27 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $113.08 | 2021-2022 | |
| Biotronik INC. | $107.41 | 2019-2023 | Biomonitor |
| Philips North America LLC | $94.06 | 2019 | |
| Bard Peripheral Vascular, INC. | $92.84 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $86.45 | 2019-2023 | Farxiga |
| Esperion Therapeutics, INC. | $71.18 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $63.23 | 2019 | |
| Chiesi USA, INC. | $50.92 | 2019-2020 | |
| Amarin Pharma, INC. | $50.90 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $46.80 | 2023-2024 | Eliquis |
| Kestra Medical Technology Services, INC. | $39.71 | 2023-2024 | Assure Wcd |
| Actelion Pharmaceuticals US, INC. | $33.21 | 2022-2024 | Uptravi, Opsumit |
| Caris Mpi, INC. | $33.19 | 2025 | Mi Cancer Seek |
| Lundbeck LLC | $32.77 | 2019 | |
| Abiomed | $29.77 | 2021 | |
| Merck Sharp & Dohme LLC | $29.62 | 2021-2022 | |
| Impulse Dynamics (USA) INC. | $23.89 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $20.26 | 2024 | |
| Alnylam Pharmaceuticals INC. | $15.07 | 2024 | Amvuttra |
| Janssen Biotech, INC. | $14.01 | 2024 | Opsumit |
| Kiniksa Pharmaceuticals, LTD. | $13.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.